» Articles » PMID: 37254089

MRI-based Radiomics Model and Nomogram for Predicting the Outcome of Locoregional Treatment in Patients with Hepatocellular Carcinoma

Overview
Journal BMC Med Imaging
Publisher Biomed Central
Specialty Radiology
Date 2023 May 30
PMID 37254089
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Prediction of locoregional treatment response is important for further therapeutic strategy in patients with hepatocellular carcinoma. This study aimed to investigate the role of MRI-based radiomics and nomogram for predicting the outcome of locoregional treatment in patients with hepatocellular carcinoma.

Methods: The initial postoperative MRI after locoregional treatment in 100 patients with hepatocellular carcinoma was retrospectively analysed. The outcome was evaluated according to mRECIST at 6 months. We delineated the tumour volume of interest on arterial phase, portal venous phase and T2WI. The radiomics features were selected by using the independent sample t test or nonparametric Mann‒Whitney U test and the least absolute shrinkage and selection operator. The clinical variables were selected by using univariate analysis and multivariate analysis. The radiomics model and combined model were constructed via multivariate logistic regression analysis. A nomogram was constructed that incorporated the Rad score and selected clinical variables.

Results: Fifty patients had an objective response, and fifty patients had a nonresponse. Nine radiomics features in the arterial phase were selected, but none of the portal venous phase or T2WI radiomics features were predictive of the treatment response. The best radiomics model showed an AUC of 0.833. Two clinical variables (hCRP and therapy method) were selected. The AUC of the combined model was 0.867. There was no significant difference in the AUC between the combined model and the best radiomics model (P = 0.573). Decision curve analysis demonstrated the nomogram has satisfactory predictive value.

Conclusions: MRI-based radiomics analysis may serve as a promising and noninvasive tool to predict outcome of locoregional treatment in HCC patients, which will facilitate the individualized follow-up and further therapeutic strategies guidance.

Citing Articles

Transfer learning radiomic model predicts intratumoral tertiary lymphoid structures in hepatocellular carcinoma: a multicenter study.

Long S, Li M, Chen J, Zhong L, Dai G, Pan D J Immunother Cancer. 2025; 13(3).

PMID: 40037925 PMC: 11881188. DOI: 10.1136/jitc-2024-011126.


Research progress of MRI-based radiomics in hepatocellular carcinoma.

Xie X, Chen R Front Oncol. 2025; 15:1420599.

PMID: 39980543 PMC: 11839447. DOI: 10.3389/fonc.2025.1420599.


Spatial patterns and MRI-based radiomic prediction of high peritumoral tertiary lymphoid structure density in hepatocellular carcinoma: a multicenter study.

Long S, Li M, Chen J, Zhong L, Abudulimu A, Zhou L J Immunother Cancer. 2024; 12(12).

PMID: 39675785 PMC: 11647298. DOI: 10.1136/jitc-2024-009879.


Prediction of initial objective response to drug-eluting beads transcatheter arterial chemoembolization for hepatocellular carcinoma using CT radiomics-based machine learning model.

Zhang X, He Z, Zhang Y, Kong J Front Pharmacol. 2024; 15:1315732.

PMID: 38344175 PMC: 10854007. DOI: 10.3389/fphar.2024.1315732.


Current status of magnetic resonance imaging radiomics in hepatocellular carcinoma: A quantitative review with Radiomics Quality Score.

Brancato V, Cerrone M, Garbino N, Salvatore M, Cavaliere C World J Gastroenterol. 2024; 30(4):381-417.

PMID: 38313230 PMC: 10835534. DOI: 10.3748/wjg.v30.i4.381.

References
1.
Ogasawara S, Chiba T, Ooka Y, Kanogawa N, Motoyama T, Suzuki E . Efficacy of sorafenib in intermediate-stage hepatocellular carcinoma patients refractory to transarterial chemoembolization. Oncology. 2014; 87(6):330-41. DOI: 10.1159/000365993. View

2.
Jiang L, Wang S, Ai Z, Shen T, Zhang H, Duan S . Development and external validation of a stability machine learning model to identify wake-up stroke onset time from MRI. Eur Radiol. 2022; 32(6):3661-3669. DOI: 10.1007/s00330-021-08493-6. View

3.
Li Z, Ren A, Yang D, Xu H, Wei J, Yuan C . Preoperatively predicting early response of HCC to TACE using clinical indicators and MRI features. BMC Med Imaging. 2022; 22(1):176. PMC: 9540694. DOI: 10.1186/s12880-022-00900-8. View

4.
Yang X, Yuan C, Zhang Y, Li K, Wang Z . Predicting hepatocellular carcinoma early recurrence after ablation based on magnetic resonance imaging radiomics nomogram. Medicine (Baltimore). 2023; 101(52):e32584. PMC: 9803514. DOI: 10.1097/MD.0000000000032584. View

5.
Li Z, Xue T, Chen X . Predictive values of serum VEGF and CRP levels combined with contrast enhanced MRI in hepatocellular carcinoma patients after TACE. Am J Cancer Res. 2016; 6(10):2375-2385. PMC: 5088300. View